GlassScriptPhysician profile
Robert Blaine Kolbe
NPI 1639118839
$4,384.92
in general payments reported to CMS, 2019-2025
33 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,006 · 2020: $466 · 2021: $53.04 · 2023: $1,077 · 2024: $539 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,860.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $597.63 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $583.84 | 2019-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $402.99 | 2021-2025 | |
| Pfizer INC. | $378.25 | 2019-2024 | |
| Lilly USA, LLC | $290.26 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $264.27 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $235.74 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.73 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $150.18 | 2019 | |
| Novartis Pharmaceuticals Corporation | $129.26 | 2019-2023 | |
| Allergan, INC. | $124.42 | 2019 | |
| Sanofi-Aventis U.S. LLC | $120.40 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.90 | 2019-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $80.45 | 2023-2025 | |
| Genentech USA, INC. | $79.96 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $72.90 | 2019-2023 | Verquvo, Belsomra |
| Astellas Pharma US INC | $67.02 | 2019-2023 | Veozah |
| Teva Pharmaceuticals USA, INC. | $60.20 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $54.49 | 2019 | |
| Sumitomo Pharma America, INC. | $47.64 | 2023 | Gemtesa |
| Exact Sciences Corporation | $45.47 | 2023-2025 | Cologuard Collection Kit |
| Ironshore Pharmaceuticals INC. | $44.28 | 2019 | |
| Lundbeck LLC | $38.64 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.77 | 2023 | |
| Abbott Laboratories | $30.03 | 2023-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $28.86 | 2025 | Concertotm |
| Sunovion Pharmaceuticals INC. | $24.28 | 2019 | |
| Amarin Pharma, INC. | $19.88 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $19.60 | 2019 | |
| Ibsa Pharma INC. | $16.50 | 2020 | |
| Dexcom, INC. | $15.94 | 2023 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $14.77 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kolbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.